Saturday 17 October 2026 Export TEVA’s income statement to Excel — free account

Teva Pharmaceutical Industries Ltd.

TEVA Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue was flat, EPS fell 296.0%, free cash flow grew 121.4% and total debt fell 3.69%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

41.52 0.41 +1.00%

Follow TEVA

Alert me

Market cap: $47.9B
P/E: 65.9×
Fwd P/E: 30.7×
Dividend yield: —
F-score: 8/9
Altman Z: 0.79
Beneish M: −2.35
Dividend safety: 52/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 113.30

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	5	4	—	2	17	1	5	4	—	6	2	—

Insider Ownership 4.72%

Capital & Financial Ratios $m

Market Cap 47,910.00

Revenue 17,315.00

Net Income 709.00

Free Cash Flow 1,401.00

Net Debt 12,937.00

Current Ratio 0.88

Debt/Equity 2.14

P/E ratio 65.90

Fwd P/E 30.70

P/S ratio 2.79

P/B ratio 6.24

Past 5Y EPS Growth —

This Y EPS Growth (30.80%)

Next Y EPS Growth 51.92%

Next Y revenue growth (3.80%)

Next 5Y EPS Growth 5.52%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 83.81%

10-year low 10-year high

P/S against its own 10 years 99.82%

10-year low 10-year high

P/B against its own 10 years 100.00%

10-year low 10-year high

EV/Sales against its own 10 years 98.60%

10-year low 10-year high

EV/FCF against its own 10 years 68.01%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2017	0.85	0.34 0.34 0.09 0.09
2016	1.36	0.34 0.34 0.34 0.34

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3,226	3,300	3,556	3,655
Receivables	3,408	3,059	3,709	3,493
Inventory	4,021	3,007	3,179	3,221
Other	504	409	539	563
	12,485	12,552	13,946	13,760

	2023	2024	2025	Q'26
Payables	2,602	2,203	2,531	2,721
ST’ Debt	1,672	1,781	1,820	4,500
Other	4,579	4,698	5,325	4,886
	12,247	12,796	13,456	15,646

Compound Annual Growth %

	10y	5y	3y
Sales	(1.29%)	0.71%	4.96%
Cash Flow	(11.42%)	6.28%	1.22%
Earnings	(1.09%)	0.00%	0.00%
Book Value	(12.45%)	(6.48%)	(2.73%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	3,982	4,142	—	—	—
’25	3,891	4,176	4,480	4,711	17,258
’24	3,819	4,164	4,332	4,229	16,544
’23	3,661	3,878	3,850	4,457	15,846
’22	3,661	3,786	3,595	3,883	14,925
’21	3,982	3,910	3,887	4,099	15,878
’20	4,357	3,870	3,978	4,454	16,659

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(40)	411	—	—	—
’25	(105)	227	369	1,158	1,649
’24	(124)	103	693	575	1,247
’23	(145)	324	5	1,184	1,368
’22	(49)	123	543	973	1,590
’21	(405)	218	529	456	798
’20	305	273	307	331	1,216

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(166)	310	—	—	—
’25	(215)	140	241	1,016	1,182
’24	(248)	7	583	450	792
’23	(282)	261	(134)	1,065	910
’22	(181)	14	423	854	1,110
’21	(417)	221	398	345	547
’20	183	181	173	168	705

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.31	(0.49)	—	—	—
’25	0.18	0.24	0.37	0.41	1.21
’24	(0.12)	(0.75)	(0.39)	(0.19)	(1.45)
’23	(0.18)	(0.77)	0.07	0.41	(0.50)
’22	(0.86)	(0.21)	0.05	(1.10)	(2.12)
’21	0.07	0.19	0.26	(0.14)	0.38
’20	0.06	0.13	(3.97)	0.14	(3.64)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	34.57	10.85	14.59	6.07	6.25	7.73	6.78	7.09	10.45	12.47	Analyst estimates 2026–2028 Powerpack
	High	65.92	38.31	25.96	20.21	13.76	13.30	11.34	11.45	22.80	31.99
People
People	Employees	56,960	51,792	42,535	40,039	40,216	37,537	36,826	37,851	36,830	33,950
	Revenue/emp, $m	0.38	0.43	0.43	0.42	0.41	0.42	0.41	0.42	0.45	0.51
Income, $m
Income, $m	Revenue	21,903	22,385	18,271	16,887	16,659	15,878	14,925	15,846	16,544	17,258
	Gross margin, %	54.14	47.42	45.41	44.63	46.38	47.83	46.72	48.25	48.74	51.79
	EBT	824	(18,379)	(2,596)	(1,265)	(4,406)	658	(3,163)	(624)	(1,284)	1,223
	EBT margin, %	3.76	(82.10)	(14.21)	(7.49)	(26.45)	4.14	(21.19)	(3.94)	(7.76)	7.09
	Net income	311	(16,449)	(2,472)	(1,000)	(4,099)	456	(2,499)	(615)	(1,959)	1,418
	Depreciation	1,524	2,112	1,842	1,722	1,557	1,330	1,308	1,153	1,059	1,002
Per share, $
Per share, $	Revenue	22.94	22.03	17.90	15.48	15.21	14.41	13.45	14.16	14.63	15.07
	Earnings	0.07	(16.26)	(2.35)	(0.91)	(3.64)	0.38	(2.12)	(0.50)	(1.45)	1.23
	Cash flow	5.47	2.19	2.40	0.69	1.11	0.72	1.43	1.22	1.10	1.44
	Capex	1.15	2.56	0.23	(0.17)	(0.47)	(0.23)	(0.43)	(0.41)	(0.40)	(0.41)
	Free cash flow	6.62	4.75	2.63	0.52	0.64	0.50	1.00	0.81	0.70	1.03
	Book value	36.64	18.45	15.47	13.81	10.10	10.20	7.75	7.26	4.76	6.91
	Shares, m	955	1,016	1,021	1,091	1,095	1,102	1,110	1,119	1,131	1,145
Valuation, ×
Valuation, ×	P/E	535.43	0.00	0.00	0.00	0.00	21.08	0.00	0.00	0.00	25.17
	P/S	1.63	0.87	0.86	0.63	0.63	0.56	0.71	0.75	1.51	2.07
	P/B	1.14	1.28	1.00	0.71	0.96	0.79	1.23	1.47	4.63	4.52
	EV/Sales	3.22	2.28	2.35	2.11	2.06	1.87	1.94	1.80	2.38	2.84
	EV/FCF	11.16	10.55	15.97	62.94	48.66	54.31	26.12	31.37	49.76	41.44
Cash, $m
Cash, $m	Operating cash flow	5,225	2,225	2,446	748	1,216	798	1,590	1,368	1,247	1,649
	Capex	1,101	2,603	239	(182)	(511)	(251)	(480)	(458)	(455)	(467)
	Free cash flow	6,326	4,828	2,685	566	705	547	1,110	910	792	1,182
Balance, $m
Balance, $m	Working capital	(1,260)	(2,539)	(528)	(210)	(159)	1,546	582	238	(244)	490
	Total debt	35,800	32,475	28,916	26,907	25,919	23,043	21,212	19,833	17,783	16,806
	Net debt	34,812	31,512	27,134	24,932	23,742	20,878	18,411	16,607	14,483	13,250
	Shareholders’ equity	34,993	18,745	15,794	15,063	11,061	11,244	8,598	8,126	5,380	7,914
Returns, %
Returns, %	ROA	0.09	(20.19)	(3.65)	(1.69)	(7.38)	0.85	(5.34)	(1.28)	(3.96)	3.52
	ROIC	1.93	(21.74)	2.02	(0.69)	(6.41)	3.34	(5.08)	1.09	3.07	6.37
	ROE	0.23	(71.10)	(15.52)	(6.48)	(30.55)	3.74	(24.65)	(6.69)	(24.27)	21.21

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TAK Takeda Pharmaceutical Co.	$61.9B	29.6×	—	+1.71% (above 0%: growing)	−4.35% (below 0%: shrinking)	−95.56% (below 0%: shrinking)	66.66%	16.51%	Compare
TEVA Teva Pharmaceutical Industries Ltd.	$47.9B	65.9×	30.7×	−0.81% (below 0%: shrinking)	n/m	+121.43% (above 0%: growing)	51.98%	(2.03%)
HLN Haleon PLC Sponsored ADR	$43.7B	22.6×	17.6×	−0.32% (below 0%: shrinking)	+40.00% (above 0%: growing)	−42.94% (below 0%: shrinking)	62.88%	25.36%	Compare
ZTS Zoetis Inc.	$32.4B	13.0×	12.3×	−0.24% (below 0%: shrinking)	+2.48% (above 0%: growing)	+17.43% (above 0%: growing)	72.73%	37.56%	Compare
UTHR United Therapeutics Corporation	$23.2B	17.6×	20.1×	−1.92% (below 0%: shrinking)	+13.99% (above 0%: growing)	+58.76% (above 0%: growing)	87.30%	42.23%	Compare
VTRS Viatris Inc.	$20.9B	— (loss-making)	61.1×	+4.88% (above 0%: growing)	n/m	+101.08% (above 0%: growing)	38.77%	0.17%	Compare
NBIX Neurocrine Biosciences, Inc.	$13.9B	19.2×	30.5×	+39.49% (above 0%: growing)	+31.19% (above 0%: growing)	+43.69% (above 0%: growing)	97.58%	15.80%	Compare
ELAN Elanco Animal Health Incorporated	$11.8B	— (loss-making)	278×	+10.23% (above 0%: growing)	+450.00% (above 0%: growing)	+35.56% (above 0%: growing)	58.33%	7.97%	Compare
RDY Dr. Reddy's Laboratories Ltd	$10.7B	32.9×	24.3×	−14.44% (below 0%: shrinking)	−70.00% (below 0%: shrinking)	−143.40% (below 0%: shrinking)	46.54%	4.81%	Compare
Median of peers	$22.1B	20.9×	24.3×	+0.74%	+13.99%	+26.50%	64.77%	16.16%

All 86 Drug Manufacturers Specialty & Generic stocks →

Teva Pharmaceutical Industries Ltd. (TEVA) key facts

Teva Pharmaceutical Industries Ltd. (TEVA) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, TEVA traded at $41.52, a market capitalization of $47.9 billion.
Return on equity was 21.2% and debt-to-equity 2.14.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 0.79 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.